# GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results

> **NCT05183243** · PHASE1 · UNKNOWN · sponsor: **Suzhou Genhouse Bio Co., Ltd.** · enrollment: 68 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Non-Small Cell Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Head and Neck Neoplasm

## Interventions

- **DRUG:** GH21 Capsule

## Key facts

- **NCT ID:** NCT05183243
- **Lead sponsor:** Suzhou Genhouse Bio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-20
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-02-20
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05183243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05183243, "GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05183243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*